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 5 
Abstract:  6 
Humans vary substantially in their willingness to take risks. In a combined sample of over one 7 
million individuals, we conducted genome-wide association studies (GWAS) of general risk 8 
tolerance, adventurousness, and risky behaviors in the driving, drinking, smoking, and sexual 9 
domains. We identified 611 approximately independent genetic loci associated with at least one 10 
of our phenotypes, including 124 with general risk tolerance. We report evidence of substantial 11 
shared genetic influences across general risk tolerance and risky behaviors: 72 of the 124 general 12 
risk tolerance loci contain a lead SNP for at least one of our other GWAS, and general risk 13 
tolerance is moderately to strongly genetically correlated (!"̂$! ~ 0.25 to 0.50) with a range of 14 
risky behaviors. Bioinformatics analyses imply that genes near general-risk-tolerance-associated 15 
SNPs are highly expressed in brain tissues and point to a role for glutamatergic and GABAergic 16 
neurotransmission. We find no evidence of enrichment for genes previously hypothesized to 17 
relate to risk tolerance.  18 
 19 
  20 
                                                        
1 Previous title: Genome-wide study identifies 611 loci associated with risk tolerance and risky behaviors. 
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Main Text: 21 
Choices in important domains of life, including health, fertility, finance, employment, and social 22 
relationships, rarely have consequences that can be anticipated perfectly. The degree of 23 
variability in possible outcomes is called risk. Risk tolerance—defined as the willingness to take 24 
risks, typically to obtain some reward—varies substantially across humans and has been actively 25 
studied in the behavioral and social sciences. An individual’s risk tolerance may vary across 26 
domains, but survey-based measures of general risk tolerance (e.g., “Would you describe 27 
yourself as someone who takes risks?”) have been found to be good all-around predictors of 28 
risky behaviors such as portfolio allocation, occupational choice, smoking, drinking alcohol, and 29 
starting one’s own business1–3.  30 
Twin studies have established that various measures of risk tolerance are moderately heritable 31 
(ℎ&~30%, although estimates in the literature vary3–5). Discovery of specific genetic variants 32 
associated with general risk tolerance could advance our understanding of how genetic 33 
influences are amplified and dampened by environmental factors; provide insights into 34 
underlying biological pathways; enable the construction of polygenic scores (indexes of many 35 
genetic variants) that can be used as overall measures of genetic influences on individuals; and 36 
help distinguish genetic variation associated with general versus domain-specific risk tolerance. 37 
Although risk tolerance has been one of the most studied phenotypes in social science genetics, 38 
most claims of positive findings have been based on small-sample candidate gene studies 39 
(Supplementary Table 11.1), whose limitations are now appreciated6. To date, only two loci 40 
associated with risk tolerance have been identified in genome-wide association studies 41 
(GWAS)7,8.  42 
Here, we report results from large-scale GWAS of self-reported general risk tolerance (our 43 
primary phenotype) and six supplementary phenotypes: “adventurousness” (defined as the self-44 
reported tendency to be adventurous vs. cautious); four risky behaviors: “automobile speeding 45 
propensity” (the tendency to drive faster than the speed limit), “drinks per week” (the average 46 
number of alcoholic drinks consumed per week), “ever smoker” (whether one has ever been a 47 
smoker), and “number of sexual partners” (the lifetime number of sexual partners); and the first 48 
principal component (PC) of these four risky behaviors, which we interpret as capturing the 49 
general tendency to take risks across domains. All seven phenotypes are coded such that higher 50 
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phenotype values are associated with higher risk tolerance or risk taking. Table 1 lists, for each 51 
GWAS, the datasets we analyzed and the GWAS sample size.   52 
 53 
Association analyses 54 
All seven GWAS were performed in European-ancestry subjects, following procedures described 55 
in a pre-specified analysis plan (https://osf.io/cjx9m/) and in Supplementary Information 56 
section 2. 57 
In the discovery phase of our GWAS of general risk tolerance (n = 939,908), we performed a 58 
sample-size-weighted meta-analysis of results from the UK Biobank (UKB, n = 431,126) and a 59 
sample of research participants from 23andMe (n = 508,782). The UKB measure of general risk 60 
tolerance is based on the question: “Would you describe yourself as someone who takes risks? 61 
Yes / No.” The 23andMe measure is based on a question about overall comfort taking risks, with 62 
five response options ranging from “very comfortable” to “very uncomfortable.” The genetic 63 
correlation9 between the UKB and 23andMe cohorts ("̂$ = 0.77, SE = 0.02) is smaller than one 64 
but high enough to justify our approach of pooling the two cohorts10.  65 
The Q-Q plot (Extended Data Fig. 3.2a) from the discovery GWAS exhibits substantial 66 
inflation (λGC = 1.41). According to the estimated intercept from a linkage disequilibrium (LD) 67 
Score regression11, only a small share of this inflation (~5%) in test statistics is due to bias. To 68 
account for this bias, we inflated GWAS standard errors by the square root of the LD Score 69 
regression intercept. 70 
We identified 124 approximately independent SNPs (pairwise r2 < 0.1) that attained genome-71 
wide significance (P < 5´10-8). These 124 “lead SNPs” are listed in Supplementary Table 3.1 72 
and shown in Fig. 1a. All have coefficients of determination (R2’s) below 0.02%, and the SNP 73 
with the largest per-allele effect is estimated to increase general risk tolerance by ~0.026 74 
standard deviations in our discovery sample (Extended Data Fig. 3.3). 75 
In the replication phase of our GWAS of general risk tolerance (combined n = 35,445), we meta-76 
analyzed summary statistics from ten smaller cohorts. Additional details on cohort-level 77 
phenotype measures are provided in Supplementary Table 1.2. The questions differ in terms of 78 
their exact wording and number of response categories, but all questions ask subjects about their 79 
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overall or general attitudes toward risk. The genetic correlation9 between the discovery and 80 
replication GWAS is 0.83 (SE = 0.13). 123 of the 124 lead SNPs were available or well proxied 81 
by an available SNP in the replication GWAS results. Out of the 123 SNPs, 94 have a 82 
concordant sign (P = 1.7×10-9) and 23 are significant at the 5% level in one-tailed t tests (P = 83 
4.5×10-8) (Extended Data Fig. 5.1). This empirical replication record matches theoretical 84 
projections that take into account sampling variation and the winner’s curse (Supplementary 85 
Information section 5).  86 
Our six supplementary GWAS—of adventurousness, four risky behaviors, and their principal 87 
component (n = 315,894 to 557,923; Supplementary Tables 1.1-1.2)—were conducted using 88 
methods comparable to those in the primary GWAS, but without a replication phase. Extended 89 
Data Fig. 3.2 (c to h) shows Q-Q plots and Extended Data Fig. 3.1 (a to f) shows Manhattan 90 
plots. 91 
Table 1 provides a summary overview of the seven GWAS. We identified a total of 865 lead 92 
SNPs across the seven GWAS. The lead SNPs are located in 611 approximately independent 93 
loci, where a locus is defined as the set of all SNPs in weak LD (pairwise r2 > 0.1) with a lead 94 
SNP. The SNP heritabilities of the seven phenotypes range from ~0.05 (for general risk 95 
tolerance) to ~0.16 (for the first PC of the four risky behaviors). 96 
 97 
Genetic overlap  98 
There is substantial overlap across the results of our GWAS. For example, 72 of the 124 general-99 
risk-tolerance lead SNPs are in loci that also contain lead SNPs for at least one of the other 100 
GWAS, including 45 for adventurousness and 49 for at least one of the four risky behaviors or 101 
their first PC. To empirically assess if this overlap could be attributed to chance, we conducted a 102 
resampling exercise under the null hypothesis that the lead SNPs of our supplementary GWAS 103 
are distributed independently of the 124 general-risk-tolerance lead loci. We strongly rejected 104 
this null hypothesis (P < 0.0001; Supplementary Information section 3.3.3). 105 
Several regions of the genome stand out for being associated both with general risk tolerance and 106 
with all or most of the supplementary phenotypes. We tested whether the signs of the lead SNPs 107 
located in these regions tend to be concordant across our primary and supplementary GWAS. We 108 
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strongly rejected the null hypothesis of no concordance (P < 3×10-30; Supplementary 109 
Information section 3.2.3), suggesting that these regions represent shared genetic influences, 110 
rather than colocalization of causal SNPs. Fig. 1b and Extended Data Fig. 3.4 show local 111 
Manhattan plots for some of these regions. The long-range LD region12 on chromosome 3 (~83.4 112 
to 86.9 Mb) contains lead SNPs from all seven GWAS as well as the most significant lead SNP 113 
from the general risk tolerance GWAS, rs993137 (P = 2.14×10–40), which is located in the gene 114 
CADM2. Another long-range LD region, on chromosome 6 (~25.3 to 33.4 Mb), covers the HLA-115 
complex and contains lead SNPs from all GWAS except drinks per week. Three candidate 116 
inversions (i.e., genomic regions that are highly prone to inversion polymorphisms; 117 
Supplementary Information section 2.9.2) on chromosomes 7 (~124.6 to 132.7 Mb), 8 (~7.89 118 
to 11.8 Mb), and 18 (~49.1 to 55.5 Mb) contain lead SNPs from six, five, and all seven of our 119 
GWAS, respectively. Finally, four other LD blocks13 that do not overlap known long-range LD 120 
or candidate inversion regions each contain lead SNPs from five of our GWAS (including 121 
general risk tolerance). The two long-range LD regions and the three candidate inversions have 122 
previously been found to be associated with numerous phenotypes, including many cognitive and 123 
neuropsychiatric phenotypes14.  124 
To investigate genetic overlap at the genome-wide level, we estimated genetic correlations with 125 
self-reported general risk tolerance using bivariate LD Score regression9. (For this and all 126 
subsequent analyses involving general risk tolerance, we used the summary statistics from the 127 
combined meta-analysis of our discovery and replication GWAS.) The estimated genetic 128 
correlations with our six supplementary phenotypes are all positive, larger than ~0.25, and highly 129 
significant (P < 2.3×10–30; Fig. 2), indicating that SNPs associated with higher general risk 130 
tolerance also tend to be associated with riskier behavior. The largest estimated genetic 131 
correlations are with adventurousness ("̂$ = 0.83, SE = 0.01), number of sexual partners (0.52, SE 132 
= 0.02), automobile speeding propensity (0.45, SE = 0.02), and the first PC of the four risky 133 
behaviors (0.50, SE = 0.02). 134 
Our estimates of the genetic correlations between general risk tolerance and the supplementary 135 
risky behaviors are substantially higher than the corresponding phenotypic correlations 136 
(Supplementary Tables 1.3 and 7.1). Although measurement error partly accounts for the low 137 
phenotypic correlations, the genetic correlations remain considerably higher even after 138 
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adjustment of the phenotypic correlations for measurement error. The comparatively large 139 
genetic correlations support the view that a general factor of risk tolerance partly accounts for 140 
cross-domain variation in risky behavior15,16 and imply that this factor is genetically influenced. 141 
The lower phenotypic correlations suggest that environmental factors are more important 142 
contributors to domain-specific risky behavior17,18. 143 
To increase the precision of our estimates of the SNPs’ effects on general risk tolerance, we 144 
leveraged the high degree of genetic overlap across our phenotypes by conducting Multi-Trait 145 
Analysis of GWAS (MTAG)19. We used as inputs the summary statistics of our GWAS of 146 
general risk tolerance, of our first five supplementary GWAS (i.e., not including the first PC of 147 
the four risky behaviors), and of a previously published GWAS on lifetime cannabis use20 148 
(Supplementary Information section 9). MTAG increased the number of general-risk-tolerance 149 
lead SNPs from 124 to 312 (Extended Data Fig. 9.1, Supplementary Table 9.1). 150 
We also estimated genetic correlations between general risk tolerance and 28 additional 151 
phenotypes (Fig. 2 and in Supplementary Table 7.1). These included phenotypes for which we 152 
could obtain summary statistics from previous GWAS, as well as five phenotypes for which we 153 
conducted new GWAS. The estimated genetic correlations for the personality traits extraversion 154 
("̂$ = 0.51, SE = 0.03), neuroticism (-0.42, SE = 0.04), and openness to experience (0.33, SE = 155 
0.03) are substantially larger in magnitude than previously reported phenotypic correlations21, 156 
pointing to substantial shared genetic influences among general risk tolerance and these traits. 157 
After Bonferroni correction, we also find significant positive genetic correlations with the 158 
neuropsychiatric phenotypes ADHD, bipolar disorder, and schizophrenia. Viewed in light of the 159 
genetic correlations we find with risky behaviors classified as externalizing (e.g., substance use, 160 
elevated sexual behavior, and fast driving), these results suggest the hypothesis that the overlap 161 
with the neuropsychiatric phenotypes is driven by their externalizing component. 162 
 163 
Biological annotation 164 
To gain insights into the biological mechanisms through which genetic variation influences 165 
general risk tolerance, we conducted a number of analyses. First, we systematically reviewed the 166 
literature that aimed to link risk tolerance to biological pathways (Supplementary Information 167 
section 11). Our review covered studies based on candidate genes (i.e., specific genetic variants 168 
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used as proxies for biological pathways), pharmacological manipulations, biochemical assays, 169 
genetic manipulations in rodents, as well as other research designs. Our review identified 132 170 
articles that matched our search criteria (Supplementary Table 11.1).  171 
Previous work has focused on five main biological pathways: the steroid hormone cortisol, the 172 
monoamines dopamine and serotonin, and the steroid sex hormones estrogen and testosterone. 173 
Using a MAGMA22 competitive gene-set analysis, we found no evidence that SNPs within genes 174 
associated with these five pathways tend to be more associated with general risk tolerance than 175 
SNPs in other genes (Supplementary Table 11.3). Further, none of the other bioinformatics 176 
analyses we report below point to these pathways.  177 
We also examined the 15 most commonly tested autosomal genes within the dopamine and 178 
serotonin pathways, which were the focus of most of the 34 candidate-gene studies identified by 179 
our literature review. We verified that the SNPs available in our GWAS results tag most of the 180 
genetic variants typically used to test the 15 genes. Across one SNP-based test and two gene-181 
based tests, we found no evidence of non-negligible associations between those genes and 182 
general risk tolerance (Fig. 1c and Supplementary Table 11.4). (We note, however, that some 183 
brain regions identified in analyses we report below are areas where dopamine and serotonin 184 
play important roles.) 185 
Second, we performed a MAGMA22 gene analysis to test each of ~18,000 protein-coding genes 186 
for association with general risk tolerance (Supplementary Information section 12.2). After 187 
Bonferroni correction, 285 genes were significant (Extended Data Fig. 12.1 and 188 
Supplementary Table 12.3). To gain insight into the functions and expression patterns of these 189 
285 genes, we looked up these genes in the Gene Network23 co-expression database. Third, to 190 
identify relevant biological pathways and identify tissues in which genes near general-risk-191 
tolerance-associated SNPs are expressed, we applied the software tool DEPICT24 to the SNPs 192 
with P values less than 10-5 in our GWAS of general risk tolerance (Supplementary 193 
Information section 12.4).  194 
Both the Gene Network and the DEPICT analyses separately point to a role for glutamate and 195 
GABA neurotransmitters, which are the main excitatory and inhibitory neurotransmitters in the 196 
brain, respectively25 (Fig. 3a and Supplementary Tables 12.4 and 12.8). To our knowledge, no 197 
published large-scale GWAS of cognition, personality, or neuropsychiatric phenotypes has 198 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/261081doi: bioRxiv preprint first posted online Feb. 8, 2018; 
 8 
pointed to clear roles both for glutamate and GABA (although glutamatergic neurotransmission 199 
has been implicated in recent GWAS of schizophrenia26 and major depression27). Our results 200 
suggest that the balance between excitatory and inhibitory neurotransmission may contribute to 201 
variation in general risk tolerance across individuals. 202 
The Gene Network and the DEPICT tissue enrichment analyses also both separately point to 203 
enrichment of the prefrontal cortex and the basal ganglia (Fig. 3b and Supplementary Tables 204 
12.4, 12.6, and 12.7). The cortical and subcortical regions highlighted by DEPICT include some 205 
of the major components of the cortical-basal ganglia circuit, which is known as the reward 206 
system in human and non-human primates and is critically involved in learning, motivation, and 207 
decision-making, notably under risk and uncertainty28,29. We caution, however, that our results 208 
do not point exclusively to the reward system.  209 
Lastly, we used stratified LD Score regression30 to test for the enrichment of SNPs associated 210 
with histone marks in 10 tissue or cell types (Supplementary Information section 12.1). 211 
Central nervous system tissues are the most enriched, accounting for 44% (SE = 3%) of the 212 
heritability while comprising only 15% of the SNPs (Extended Data Fig. 12.3a and 213 
Supplementary Table 12.2). Immune/hematopoietic tissues are also significantly enriched. 214 
While a role for the immune system in modulating risk tolerance is plausible given prior 215 
evidence of its involvement in several neuropsychiatric disorders26,27, future work is needed to 216 
confirm this result and to uncover specific pathways that might be involved.  217 
 218 
Polygenic prediction  219 
We constructed polygenic scores of general risk tolerance to gauge their potential usefulness in 220 
empirical research (Supplementary Information section 10). We used the Add Health, HRS, 221 
NTR, STR, UKB-siblings, and Zurich cohorts as validation cohorts (Supplementary Table 1.1 222 
provides an overview of these cohorts; the UKB-siblings cohort comprised individuals with at 223 
least one full sibling in the UKB). For each validation cohort, we constructed the score using 224 
summary statistics from a meta-analysis of our discovery and replication GWAS that excluded 225 
the cohort. Our measure of predictive power is the incremental R2 (or pseudo-R2) from adding 226 
the score to a regression of the phenotype on sex, birth year, and the top ten principal 227 
components of the genetic relatedness matrix.  228 
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Our preferred score was constructed with LDpred31. In the UKB-siblings cohort, which is our 229 
largest validation cohort (+	~ 35,000), the score’s predictive power is 1.6% for general risk 230 
tolerance, 1.0% for the first PC of the four risky behaviors, 0.8% for number of sexual partners, 231 
0.6% for automobile speeding propensity, and ~0.15% for drinks per week and ever smoker. 232 
Across our validation cohorts, the score is also predictive of several personality phenotypes and a 233 
suite of real-world measures of risky behaviors in the health, financial, career, and other domains 234 
(Extended Data Figs. 10.1-10.2 and Supplementary Tables 10.1-10.3). The incremental R2 we 235 
observe for general risk tolerance is consistent with the theoretical prediction, given the SNP 236 
heritability of general risk tolerance (Table 1) and the imperfect genetic correlations across the 237 
GWAS and validation cohorts32,33 (Supplementary Information section 10.4). 238 
 239 
Discussion 240 
Our results provide insights into biological mechanisms that influence general risk tolerance. Our 241 
bioinformatics analyses point to the role of gene expression in brain regions that have been 242 
identified by neuroscientific studies on decision-making, notably the prefrontal cortex, basal 243 
ganglia, and midbrain, thereby providing convergent evidence with that from neuroscience28,29. 244 
Yet our analyses failed to find evidence for the main biological pathways that had been 245 
previously hypothesized to influence risk tolerance. Instead, our analyses implicate genes 246 
involved in glutamatergic and GABAergic neurotransmission, which were heretofore not 247 
generally believed to play a role in risk tolerance. 248 
Although our focus has been on the genetics of general risk tolerance and risky behaviors, 249 
environmental and demographic factors account for a substantial share of these phenotypes’ 250 
variation. We observe sizeable effects of sex and age on general risk tolerance in the UKB data 251 
(Extended Data Fig. 1.1), and life experiences have been shown to affect both measured risk 252 
tolerance and risky behaviors (e.g., refs. 34,35). The data we have generated will allow 253 
researchers to construct and use polygenic scores of general risk tolerance to measure how 254 
environmental, demographic, and genetic factors interact with one another. 255 
For the behavioral sciences, our results bear on the ongoing debate about the extent to which risk 256 
tolerance is a “domain-general” as opposed to a “domain-specific” trait. Low phenotypic 257 
correlations in risk tolerance across decision-making domains have been interpreted as 258 
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supporting the domain-specific view17,18. Across the risky behaviors we study, we find that the 259 
genetic correlations are considerably higher than the phenotypic correlations (even after the latter 260 
are corrected for measurement error) and that many lead SNPs are shared across our phenotypes. 261 
These observations suggest that the low phenotypic correlations across domains are due to 262 
environmental factors that dilute the effects of a genetically-influenced domain-general factor of 263 
risk tolerance.  264 
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Figure 1 | Manhattan plots. In all panels, the x-axis is chromosomal position; the y-axis is the 378 
significance on a −log10 scale; the horizontal dashed line marks the threshold for genome-wide 379 
significance (P = 5×10−8); and each approximately independent (pairwise r2 < 0.1) genome-wide 380 
significant association (“lead SNP”) is marked by a red ×. a, Manhattan plots for the discovery 381 
GWAS of general risk tolerance. b, Local Manhattan plots of two genomic regions that contain 382 
lead SNPs for all seven of our GWAS. The gray background marks the locations of long-range 383 
LD or candidate inversion regions. c, Local Manhattan plots of the loci around the 15 most 384 
commonly tested candidate genes in the prior literature on the genetics of risk tolerance. Each 385 
locus comprises all SNPs within 500 kb of the gene’s borders that are in LD	("& > 0.1) with a 386 
SNP in the gene.  The 15 plots are concatenated and shown together in the panel, divided by the 387 
black vertical lines. The 15 genes are not particularly strongly associated with general risk 388 
tolerance or the risky behaviors, as can be seen by comparing the results within each row across 389 
panels b and c (the three rows correspond to the GWAS of general risk tolerance, 390 
adventurousness, and the first PC of the four risky behaviors).  391 
 392 
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 394 
Figure 2 | Genetic correlations with general risk tolerance. The genetic correlations were 395 
estimated using bivariate LD Score (LDSC) regression9. Error bars show 95% confidence 396 
intervals. For the supplementary phenotypes and the additional risky behaviors, green bars 397 
represent significant estimates with the expected signs, where higher risk tolerance is associated 398 
with riskier behavior. For the other phenotypes, blue bars represent significant estimates. Light 399 
green and light blue bars represent genetic correlations that are statistically significant at the 5% 400 
level, and dark green and dark blue bars represent correlations that are statistically significant 401 
after Bonferroni correction for 34 tests (the total number of phenotypes tested). Grey bars 402 
represent correlations that are not statistically significant at the 5% level. 403 
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Figure 3 | Results from selected biological analyses. a, DEPICT gene-set enrichment diagram. 404 
We identified 93 reconstituted gene sets that are significantly enriched (FDR < 0.01) for genes 405 
overlapping loci associated with general risk tolerance; using the Affinity Propagation method36, 406 
these were grouped into the 13 clusters displayed in the graph. Each cluster was named after the 407 
most significant gene set it contained, and each cluster’s color represents the permutation P value 408 
of its most significant gene set. The “synapse part” cluster includes the gene set “glutamate 409 
receptor activity,” and several members of the “GABAA receptor activation” cluster are defined 410 
by gamma-aminobutyric acid signaling. Overlap between the named representatives of two 411 
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clusters is represented by an edge. Edge width represents the Pearson correlation ρ between the 412 
two respective vectors of gene membership scores (ρ < 0.3, no edge; 0.3 ≤ ρ < 0.5, thin edge; 0.5 413 
≤ ρ < 0.7, intermediate edge; ρ ≥ 0.7, thick edge). b, Results of DEPICT tissue enrichment 414 
analysis using GTEx data. The panel shows whether the genes overlapping loci associated with 415 
general risk tolerance are significantly overexpressed (relative to genes in random sets of loci 416 
matched by gene density) in various tissues. Tissues are grouped by organ or tissue type. The 417 
orange bars correspond to tissues with significant overexpression (FDR < 0.01). The y-axis is the 418 
significance on a −log10 scale. 419 
 420 
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Table 1 | GWAS results  
 
GWAS Cohorts analyzed n Mean !"  LD Score intercept (SE) # lead SNPs SNP h2 (SE) 
General risk tolerance (disc. GWAS) UKB; 23andMe 939,908 1.85 1.04 (0.01) 124 0.046 (0.001) 
General risk tolerance (rep. GWAS) 10 indep. cohorts 35,445 1.03 1.00 (0.07) 0 -- 
General risk tolerance (disc. + rep.) UKB; 23andMe; 10 indep. cohorts 975,353 1.87 1.04 (0.01) 132 0.045 (0.001) 
Adventurousness 23andMe 557,923 1.98 1.05 (0.01) 167 0.098 (0.002) 
Automobile speeding propensity UKB 404,291 1.53 1.03 (0.01) 42 0.079 (0.003) 
Drinks per week UKB 414,343 1.61 1.03 (0.01) 85 0.085 (0.003) 
Ever smoker UKB; TAG Consortium 37 518,633 1.97 1.05 (0.01) 223 0.109 (0.003) 
Number of sexual partners UKB 370,711 1.77 1.04 (0.01) 118 0.128 (0.003) 
First PC of the four risky behaviors UKB 315,894 1.77 1.05 (0.01) 106 0.156 (0.004) 
The table provides an overview of the GWAS of our primary and supplementary phenotypes. “n”: GWAS sample size; “Mean !"”: 
mean GWAS chi-squared statistics across HapMap3 SNPs with minor allele frequency (MAF) greater than 0.01; “LD Score 
intercept”: estimate of the intercept from a LD Score regression11 using HapMap3 SNPs with MAF greater than 0.01; “# lead SNPs”: 
number of lead SNPs, calculated after the associated statistics have been adjusted using the estimated LD score intercept; “SNP h2”: 
SNP heritability estimated with the Heritability Estimator from Summary Statistics (HESS) method38 using 1000 Genomes phase 3 
SNPs with MAF greater than 0.05; “disc.”: discovery; “rep.”: replication; “indep.”: independent.  
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